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Type 2 diabetes mellitus
Oral peptide delivery
GLP-1
A B S T R A C T
The delivery of therapeutic peptides via the oral route remains one of biggest challenges in the pharmaceutical
industry. Recently, we have described an alternative improved drug delivery system for peptide delivery via the
oral route, consisting of a lipidic nanocapsule. Despite the striking effects observed, it is still essential to develop
strategies to strengthen the nanocarriers’ glucagon-like peptide-1 (GLP-1) secretory effect of the nanocarrier
and/or prolong its antidiabetic effect in vivo to facilitate its translation into the clinic. For this purpose, we
developed and compared different fatty acid-targeted lipid and polymeric nanoparticles and evaluated the L cell
stimulation induced by the nanocarriers in murine L cells in vitro and in normal healthy mice in vivo. We further
examined the antidiabetic effect in vivo in an obese/diabetic mouse model induced by high-fat diet feeding and
examined the effect of the oral administration frequency. Among the tested nanocarriers, only lipid-based na-
nocarriers that were surface-modified with DSPE-PEG2000 on the surface were able to significantly strengthen the
biological effect of the nanocarriers. They increased endogenous GLP-1 levels up to 8-fold in vivo in normo-
glycemic mice. Moreover, they effectively prolonged the in vivo antidiabetic effect by normalizing the plasma
glucose levels in obese/diabetic mice following long-term treatment (one month). Ultimately, the targeted na-
nocarriers were as effective when the administration frequency was reduced from once daily to once every other
day.
1. Introduction
Therapeutic peptides (more than 60 peptide drugs [1]) are now
commercialized via parenteral administration [2]. The delivery of
therapeutic peptides via the oral route remains a challenge, especially
regarding the low oral bioavailability (less than 1%) of these peptides.
Despite these challenges, the advantages of the oral route are remark-
able, ameliorating the shortcomings of the parenteral route (e.g., needle
phobia, non-patient convenience) [3,4]. The development of oral de-
livery systems that allow the absorption of peptides into the systemic
circulation is still one of the greatest challenges for the pharmaceutical
industry [5]. This is especially true in the treatment of chronic diseases
such as type 2 diabetes mellitus (T2DM), where daily injections can be
required. T2DM consists of an array of dysfunctions, including a
marked insulin resistance, a defect in insulin-mediated glucose uptake
in muscle, a disruption of adipocytes function, an impaired insulin ac-
tion in the liver and eventually a complete dysfunction of the pancreatic
β-cells [6]. Glucagon-like peptide-1 (GLP-1) is secreted from en-
teroendocrine L cells in the gut and has emerged as an antidiabetic
peptide due to its multiple physiological effects related to T2DM. GLP-1
promotes insulin secretion and decreases glucagon secretion in the
pancreas in a glucose-dependent manner, increasing insulin sensitivity;
its effects disappear, reducing the risk of unwanted hypoglycemic
events [7]. The oral administration of these gut hormone mimetic
peptides could simulate the normal physiological pathway of native
incretin peptides [8], which can access the liver in much higher con-
centrations through the hepatic portal vein, avoiding extensive systemic
exposure and its associated side effects [9].
The first oral GLP-1 analog has reached the market (semaglutide,
Rybelsus®, NovoNordisk), representing a major breakthrough in the
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oral delivery of peptides [10]. The formulation is based on the co-ad-
ministration of the peptide with a permeation enhancer (sodium N-[8-
(2-hydroxybenzoyl) amino] caprylate (SNAC). The formulation pre-
sents two main limitations: 1) small differences in the peptide or the
SNAC substantially affect the absorption efficacy (variable bioavail-
ability) and 2) according to the authors, the co-administration of SNAC
with liraglutide failed to provide circulating levels of liraglutide (the
efficacy is limited to the administration of the GLP-1 analog semaglu-
tide (half-life of 165 h)). We have recently described what we believe
would represent an alternative improved drug delivery system for the
oral delivery of peptides, consisting of a lipid-based nanocapsule [11].
Regardless of the encouraging properties of nanomedicines [11–13],
they still must demonstrate superiority to standard formulations in-
corporating functional excipients in oral peptide delivery [14]. We have
developed a dual-action approach that synergizes the biological effect
of nanocarriers (inducing endogenous GLP-1 secretion) with that of the
encapsulated molecule (increased absorption of the encapsulated pep-
tide). In our proof-of-concept studies, we encapsulated exenatide (half-
life of 2.5 h) as a model GLP-1 analog to demonstrate that our strategy
we can achieve a therapeutic effect with a short half-life peptide [11].
We conducted a long-term treatment study (one month) in a chronic
T2DM model in mice. Our results demonstrated that this strategy was at
least as efficient as the marketed drug (Byetta®, subcutaneous injection)
and could even be more potent for improving insulin resistance, oral
glucose tolerance and hepatic steatosis [11]. In addition, our approach
offers an important advantage over current strategies for oral delivery
of incretin mimetic peptides, providing increased endogenous GLP-1
stimulation. These findings allow the potential use of a lower dose in a
foreseen application and proven effectiveness with a short half-life
peptide, avoiding potential associated toxicity related to the accumu-
lation of a long half-life peptide following daily administrations.
Despite the striking effects observed, it is still essential to develop
strategies to strengthen the nanocarrier GLP-1 secretory effect and/or
prolong its antidiabetic effect in vivo to facilitate its translation into the
clinic. We hypothesized that this could be attained by modulating the
effect of our lipid-based drug delivery system by tailoring the surface of
the nanocarriers.
Enteroendocrine L cells express various G protein-coupled receptors
(GPCRs) that are activated by different dietary nutrients present in the
lumen to modulate the secretion of hormones (e.g., GLP-1) [15]. Each
GPCR has its own ligands, thereby correspondingly modulating the
different gut hormones secreted from L cells. For instance, free fatty
acid receptors FFAR2 and FFAR3, also known as GPR43 and GPR41, are
activated by short-chain fatty acids (SCFAs) (e.g., acetate, propionate,
butyrate), stimulating GLP-1 secretion [16]. SCFA propionate displays
similar agonism both on FFAR2 and FFAR3, whereas acetate and bu-
tyrate only have high affinity for FFAR2 and FFAR3, respectively
[17,18]. In addition, propionate is an end-product of fermentation and
thus is not cross-metabolized by the microbiota, unlike acetate and
butyrate [19]. We hypothesized that grafting propionate on the surface
of our lipid-based nanosystem could lead to an increased GLP-1 secre-
tory effect by directly targeting L cells.
In the present study, we developed targeted nanoparticles towards
increased L cell stimulation to improve oral peptide delivery in incretin-
based diabetes treatment. We compared the strategies in both lipid
(lipid nanocapsules) and polymeric (PLGA) nanoparticles in a murine L
cell line in vitro and in normal healthy mice in vivo. We also examined
their antidiabetic effect in vivo in an obese/diabetic mouse model in-
duced by a high-fat diet (HFD), examining the effect of the oral ad-
ministration frequency.
2. Materials and methods
2.1. Materials
Exenatide (exenatide acetate) (EXE) was purchased from Bachem
(Bubendorf, Switzerland). Labrafac® WL 1349 (caprylic/capric acid
triglycerides) and Peceol® (oleic acid mono-, di- and triglycerides) were
kindly provided by Gattefossé (Saint-Priest, France). Lipoid® S 100
(soybean lecithin at 94% of phosphatidylcholines) was a gift from
Lipoid GmbH (Ludwigshafen, Germany). Solutol® HS15 (mixture of free
PEG 660 and PEG 660 12-hydroxystearate, Mw 870 Da) and Span® 80
(sorbitan oleate) were purchased from Sigma-Aldrich (St. Louis, USA).
The 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy
(polyethylene glycol)2000] (DSPE-PEG2000), 1,2-distearoyl-sn-glycero-
3 phosphoethanolamine-N-[polyethylene glycol)-2000]-propionate
(DSPE-PEG2000-CH2-CH2-COOH), poly(lactide-co-glycolide) (10k, d,l-
LA/GA: 50:50)-block-[poly(ethylene glycol)-2000]-propionate (PLGA-
PEG2000-CH2-CH2-COOH), and poly(lactide-co-glycolide) (10k, d,l-LA/
GA: 50:50)-block-[poly(ethylene glycol)-2000] methyl ether (PLGA-
PEG2000) were obtained from Nanosoft Polymers (Winston-Salem,
USA). Lecithin, sodium chloride (NaCl), saponin, pepsin, Triton-X 100,
sodium taurocholate and dimethyl sulfoxide (DMSO), 3-(4,5- dimethyl-
thiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) were purchased
from Sigma-Aldrich (St. Louis, USA). Total GLP-1 (ver.2) and active
GLP-1 assay kits were purchased from Meso Scale Discovery (Maryland,
USA). The Exendin-4 enzyme immunoassay kit was purchased from
Phoenix Europe GmbH (Karlsruhe, Germany). The Ultrasensitive Mouse
Insulin ELISA Kit was purchased from Mercodia AB (Uppsala, Sweden).
Matrigel™ was obtained from BD Bioscience (Belgium). Dipeptidyl
peptidase IV (DPP-IV) inhibitor was purchased from Millipore (St.
Charles, USA). Dulbecco's Modified Eagle's Medium (DMEM)-GlutaMAX
(5.5 Mm glucose), fetal bovine serum (FBS), penicillin-streptomycin (P/
S), trypsin (0.25%)-EDTA (0.02%) and phosphate-buffered saline (PBS)
were also used and purchased from Thermo Fisher Scientific
(Invitrogen, Belgium). DiD (DiIC18(5) solid (1,1′-ioctadecyl-3,3,3′,3′-
tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate salt)) was
obtained from Thermo Fisher Scientific (Invitrogen, UK). All chemical
reagents utilized in this study were of analytical grade.
2.2. Preparation and characterization of non-targeted and targeted
nanoparticles
2.2.1. Preparation of non-targeted and targeted lipid-based nanosystems
The non-targeted lipidic nanosystem (EXE RM LNC) containing ex-
enatide-encapsulated reverse micelles (EXE RM) and modified lipid
nanocapules (LNC) was prepared as described by Xu et al. [11]. First,
exenatide-encapsulated reverse micelles (EXE RM) were prepared by
stirring under high speed a mixture consisting of Span® 80 (surfactant)
and Labrafac® WL 1349 (oil) with a ratio of 1:5 wt. During stirring,
50 μL of drug solution was dripped into the mixture. Second, LNC were
produced by the phase inversion process, with slight modifications. The
mixture of 769.5 mg Labrafac® WL 1349, 85.5 mg Peceol®, 13.4 mg
Lipoid® S100, 120 mg Solutol® HS15, 50 mg sodium chloride (NaCl)
and 1.025 mL of MilliQ water was stirred at 200 rpm for 5 min. Three
progressive heating/cooling cycles (between 50 °C and 67 °C) were
conducted. In the last cycle, 500 μL of pre-heated EXE RM was added to
the mixture when the temperature was approximately at 3 °C above the
phase inversion zone (PIZ; 59–61.5 °C). Finally, 2.5 mL of cold water
was added to reach the PIZ temperature under high-speed stirring for
2 min. The blank non-targeted nanosystems (RM LNC) were produced
using the same procedure without adding the drug solution.
2.2.2. Preparation of DiD-labeled non-targeted and targeted lipid-based
nanosystems
DiD-labeled RM LNC were prepared by adding 225 μg of DiD to the
mixture. Namely, 45 μL of DiD in ethanol (5 mg/mL) was added to the
vial and then heated in a water bath until the organic solvent was
completely evaporated. Subsequently, Labrafac® WL 1349 was added to
the same vial and mixed with DiD in the water bath until the DiD was
completely dissolved in the oil phase. The mixture was then cooled
down to room temperature, other components were added and the
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preparation process was continued as above described.
2.2.3. Preparation of PEGylated reverse micelle-loaded lipid nanocapsules
with or without propionate
PEGylated reverse micelle-loaded lipid nanocapsules with or
without propionate (RM LNC PEG or RM LNC PEG-PRO, respectively)
were produced by incubating DSPE-PEG2000 or DSPE-PEG2000-CH2-CH2-
COOH, respectively, with RM LNC at a concentration of 5 mg/mL,
under gentle stirring at 37 °C for 4 h. During the incubation, the sus-
pension was vortexed every 15 min and then quenched in an ice bath
for 1 min [20].
2.2.4. Preparation of PEGylated PLGA nanoparticles with or without
propionate
PLGA nanoparticles were prepared by the modified double emulsi-
fication method [21]. Typically, 25 mg of PLGA-PEG2000 or PLGA-
PEG2000-propionate was dissolved in 1 mL dichloromethane (DCM). For
PLGA-PEG2000 NPs, 50 μL of an aqueous (drug) solution (in MilliQ
water) was dropped into the oil phase under sonication (Digital sonifier
450, Branson, USA) at 30% amplitude for 30 s to form the primary
water-in-oil emulsion. This primary emulsion was poured into 2 mL of a
second aqueous phase containing 2% (w/v) saponin under sonication at
30% amplitude for 30 s to form the water-in-oil-in-water emulsion. This
step was repeated twice. The emulsion was added to another 10 mL of
2% saponin solution under magnetic stirring to evaporate the organic
solvent. The final nanoparticle suspension was centrifuged at
15,000 rpm for 30 min at 4 °C (Avanti® J-E centrifuge, Beckman
Coulter, USA) and thoroughly washed with MilliQ water. PLGA-
PEG2000-PRO NPs were prepared using 1% saponin and sonication at
30% amplitude for 15 s instead.
2.2.5. Quantification of exenatide
The exenatide encapsulated within PEGylated RM LNC was quan-
tified by high-performance liquid chromatography (HPLC, Shimadzu,
Japan) using a gradient method as previously described by Xu et al.
[11]. Briefly, a Kinetex® EVO C18 column (100 Å, 2.6 μm,
150 × 4.6 mm) (Phenomenex, USA) with a security guard column
(Phenomenex, USA) was used at room temperature. The aqueous mo-
bile phase comprised 0.05% (v/v) trifluoroacetic acid (TFA) in water,
and the organic mobile phase consisted of 0.05% (v/v) in acetonitrile. A
gradient system was developed with an initial ratio of 10:90 (v/v,
aqueous:organic phase) at a flow rate of 1 mL/min, which was linearly
changed to 90:10 (v/v) over 10 min and kept constant for the next
minute. Then, the ratio was linearly changed to the initial composition
in the next 1.5 min and stabilized for the last minute. The injection
volume was 20 μL, and the detection wavelength was 220 nm. The
retention time was 5.9 min, and the limit of detection and limit of
quantification were 1.1 ± 0.4 μg/mL and 3.3 ± 1.1 μg/mL, respec-
tively.
2.2.6. Characterization of NPs
The mean diameter and polydispersity index (PDI) of PEGylated RM
LNC and PLGA NPs were determined using a Zetasizer Nano ZS
(Malvern Instruments Ltd., Worcestershire, UK) by dynamic light scat-
tering (DLS). The zeta potential was determined by Laser Doppler ve-
locimetry (LDV) using the same device. For the measurement, 5 μL of
the nanocapsule suspension was dispersed in 995 μL of ultrapure water.
All measurements were performed in triplicate.
In addition to their size, zeta potential and PDI, EXE RM LNC and
PEGylated EXE RM LNC were also characterized based on their drug
encapsulation efficiency (EE, %). To calculate the total drug content,
50 μL of LNC suspension were dissolved in 950 μL of methanol followed
by strong vortexing. Free and encapsulated exenatide were separated by
ultrafiltration using Amicon® centrifuge filters (MWCO 30 kDa, 4000 g,
4 °C, 20 min) (Millipore). Filtrates were further diluted using a 1:2
dilution factor. The exenatide in the filtrate and the exenatide dissolved
in methanol were quantified using the above-described HPLC method.
The EE was calculated using the following equation:
EE (%) = (total amount of exenatide – free exenatide)/(total
amount of exenatide) × 100.
2.3. Nanocapsule stability and drug release in stimulated gastrointestinal
fluids
2.3.1. PEGylated nanocapsule stability in stimulated gastrointestinal fluids
The in vitro stability of PEGylated EXE RM LNC, with or without
propionate as a ligand, was evaluated in four simulated intestinal
media: Fasted State-Simulated Gastric Fluid (FaSSGF) with and without
pepsin, Fasted State-Simulated Intestinal Fluid (FaSSIF) and Fed State-
Simulated Intestinal Fluid (FeSSIF). The composition of these bior-
elevant simulated fluids has been previously described [11]. The in-
fluence of gastric and intestinal conditions on nanocapsule stability was
evaluated based on the nanocapsule size and the PDI. PEGylated EXE
RM LNC were incubated in the aforementioned biomimetic media at
37 °C (100 μL of nanocapsules in 10 mL of medium) under gentle
stirring. At different time points (0, 0.5, 1 and 2 h for stimulated gastric
media and 0, 0.5, 1, 3 and 6 h for stimulated intestinal media and
FeSSIF), samples were withdrawn and analyzed by DLS.
2.3.2. In vitro drug release studies
Drug release from PEGylated EXE RM LNC was evaluated in FaSSGF
in the absence of pepsin and in FaSSIF media for 2 h and 6 h, respec-
tively. Studies were performed using the dialysis method. Briefly, 1 mL
of PEGylated EXE RM LNC was placed in disposable dialysis membranes
(MWCO 100 kDa) (Float-A-Lyzer®G2, Microfloat, Spectrum labs, USA)
and introduced into 50-mL falcon tubes containing 35 mL of medium at
37 °C under magnetic stirring. At predetermined times, 50 μL of the
sample was withdrawn and dissolved in 950 μL of methanol. The
concentration of exenatide was determined by HPLC as described
above.
2.4. In vitro cell studies
2.4.1. Cell cultures
The intestinal murine L cell line GLUTag was kindly provided by Dr.
Daniel Drucker (University of Toronto, Canada). GLUTag cells were
used from passages 17 to 25. Cells were grown in DMEM GlutaMAX
(5.5 mM glucose) supplemented with 10% (v/v) inactivated FBS and
1% (v/v) P/S (complete DMEM medium) at 37 °C with 5% CO2 supply.
Cells were passaged every 4–5 days.
2.4.2. Cytotoxicity studies
In vitro cytotoxicity studies of unloaded PEGylated RM LNC and
PEGylated PLGA NPs were performed in GLUTag cells using nano-
particle concentrations calculated previously using the 3-(4,5-di-
methylthiazol-2-yl)-(2,5-diphenyltetrazolium bromide) (MTT) colori-
metric assay [22]. GLUTag cells (5 × 104 cells per well) were seeded on
Matrigel™-coated (10 μL/mL of medium) 96-well plates. After washing
the plates with prewarmed PBS buffer (x3), 100 μL of the nanoparticle
suspension at increasing nanocapsule concentrations (0.5–10 mg/mL)
and at increasing PLGA nanoparticle concentration (0.1–8 mg/mL) was
dispersed in medium (without FBS) and co-incubated with GLUTag cells
at 37 °C for 2 h. After incubation, the supernatants were replaced with
100 μL of 0.5 mg/mL MTT for 3 h. The purple formazan crystals were
dissolved in 200 μL of DMSO for absorbance determination at 560 nm
using a MultiSksan EX plate reader (Thermo Fisher Scientific, USA).
Cells with Triton-X 100 (100% dead) and cells with culture medium
(100% alive) were considered positive and negative controls, respec-
tively. Tests were performed in triplicate.
2.4.3. In vitro GLP-1 secretion
GLUTag (1.8 × 105 cells per well) were seeded onto Matrigel™-
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coated 24-well cell culture plates and allowed to adhere for 24 h. The
next day, the plate was gently washed using prewarmed PBS. The
GLUTag cells were then co-incubated with DMEM GlutaMAX without
FBS or unloaded PEGylated NPs (RM LNC and PLGA NPs with or
without ligand). The media contained DPP-IV inhibitor at a final con-
centration of 50 μM (Millipore, St. Charles, MO, USA). To test the effect
of different nanoparticle concentrations on GLP-1 secretion, we used
0.5–2 mg/mL nanocapsule and 0.1–3 mg/mL nanoparticle concentra-
tions, respectively. After 2 h of incubation at 37 °C, supernatants were
collected by centrifugation (250 g, 5 min at 4 °C; Centrifuge 5804 R,
Eppendorf AG, Hamburg, Germany) and preserved at −80 °C. Cells
were collected in PBS containing DPP-IV inhibitor. Cell extracts con-
taining GLP-1 were obtained after three freeze-thaw cycles followed by
centrifugation at 250g for 5 min at 4 °C. Total GLP-1 concentration was
determined using a Total GLP-1 ELISA kit (Meso Scale Delivery,
Gaithersburg, USA). GLP-1 secretion is expressed as the amount of GLP-
1 detected in the supernatants plus cells. GLP-1 secretion was calculated
using the following equation:
GLP-1 secretion = Cextracellular/(Cintracellular + Cextracellular)
2.5. In vivo studies
2.5.1. Animals
All protocols involving animal studies were approved by the
Université catholique de Louvain ethical committee on animal experi-
ments (2018/UCL/MD/45; laboratory agreement LA1230418) and
conducted in accordance with the Belgian legislation regarding the
protection of laboratory animals (Royal Decree of 29 May 2013).
2.5.2. Total GLP-1 secretion of ligand-conjugated and non-conjugated
PEGylated NPs in normoglycemic mice
To test PEGylated RM LNC (with or without propionate), C57BL/6J
male mice (20–25 g, 10 weeks; Janvier Laboratories, France) were
randomly divided into four groups (8 mice each). The animals were
fasted overnight and allowed ad libitum access to water before the
experiments. Mice were treated with blank RM LNC, blank PEGylated
RM LNC and blank PEGylated RM LNC-PRO (~1.62 mg/g nanoparticle
dose). Control mice were treated by oral gavage with an equivalent
volume of MilliQ water. Blood samples were withdrawn from the tip of
the tail vein at 60 and 180 min after oral administration. DPP-IV in-
hibitor (20 μL per mL of blood) was added to the tubes for the sample
collection. The blood samples were maintained on ice and centrifuged
(3000 rpm, 10 min at 4 °C) right after the study, and the plasma was
stored (−80 °C) until analysis. The total GLP-1 ELISA kit (Meso Scale
Delivery, USA) was used to quantify the total GLP-1 levels.
In the case of PEGylated PLGA NPs (with or without conjugated
propionate), 4 mice per group and a 200-mg/kg nanoparticle dose were
used instead. The blood collection and total GLP-1 secretion analysis
was conducted following the protocol described above. Total GLP-1
levels were measured under the same conditions.
2.5.3. Nanocapsule distribution in the obese/diabetic mouse small intestine
and colon
Male C57BL/6J mice (8 weeks old) were randomly divided into 4
groups (n = 4 per group). After acclimation (2 weeks), the mice un-
derwent 10 weeks of HFD feeding (rodent diet with 60% fat and 20%
carbohydrates (in kcal %)) (D12492i, Research Diets, USA). Before the
experiments, the mice were fasted overnight with free access to water.
For evaluation of the nanocapsule distribution in the small intestine and
colon, DiD-labeled nanocapsules, including RM LNC, PEGylated RM
LNC and PEGylated RM LNC-PRO (~1.62 mg/g nanoparticle dose),
were administered orally. Control mice were orally administered an
equivalent volume of MilliQ water. Sections of duodenum, jejunum,
ileum and colon were excised 1 h post-administration and subsequently
flash frozen in Optimal Cutting Temperature compound (OCT). For all
tissues, 6-μm-thick sections were cut using a Leica CM-3050-S cryostat.
The tissue sections were briefly fixed in 4% paraformaldehyde for
5 min. After washing the PBS containing 0.02% polysorbate 20, the
slides were mounted with VECTASHIELD Hard Set Mounting Medium
containing DAPI. The samples were examined by CLSM using a Zeiss
confocal microscope (LSM 150) to capture serial images. The data were
analyzed using Axio Vision software (version 4.8).
2.5.4. Mucus extraction from obese/diabetic mouse intestine
Untreated 10 week-HFD-induced diabetic mice were fasted over-
night with free access to water. Prior to mucus extraction, the mice
were sacrificed by cervical dislocation. The protocol followed was
adapted from Wang et al. [23]. Briefly, the duodenum and apical je-
junum were dissected and placed in a Petri dish, following a very gentle
flush with PBS to remove decal matter in the intestine. The syringe with
a 19.5-gauge needle was used to deliver PBS gently though one open
end of the intestinal segments. The intestinal segments were cut long-
itudinally using surgical scissors. Then, the mucus was scraped off the
intestinal segments using a cell scraper (1.8 cm blade, Falcon®) and
transferred to a clean tube. The isolated mucus was stored at−20 °C for
further mucus diffusion and mucus stability studies.
2.5.5. Single particle tracking and confocal microcopy
DID RM LNC, DID RM LNC PEG and DID RM LNC PEG-PRO were
diluted in water or small intestine mucus of mice and mixed by gentle
stirring. A volume of 5 μL was placed on a microscopy glass slide sealed
with an adhesive spacer (S24737, Secure-Seal™ Spacer, Thermo Fisher)
and a cover glass (#1.5).
For single particle tracking, fluorescent signals were recorded using
a spinning disk confocal microscope (Nikon Eclipse Ti, Tokyo, Japan)
equipped with an MLC 400 B laser box (Agilent Technologies, Santa
Clara, CA, USA), a Yokogawa CSU-X1 confocal spinning disk device
(Andor, Belfast, UK), an iXon ultra EMCCD camera (Andor Technology,
Belfast, UK) and NIS Elements software (Nikon, Japan). A 100x oil
immersion objective lens (Plan Apo VC 100× oil, 1.4 NA, Nikon,
Japan) was used. A stage-top incubator (37 °C, Tokai Hit) in combi-
nation with an objective lens heater (Biotechs) was used during ima-
ging. Movies of 100 frames with a temporal resolution of 43.9 ms were
recorded 5–10 μm above the coverslip. No further analysis could be
performed due to either NP accumulation in distinct parts of the mucus
or leakage of the fluorescent label so that individual NPs could no
longer be seen or analyzed.
The samples prepared for single particle tracking were also studied
by laser scanning confocal microscopy. Images were recorded on a
Nikon A1R HD Confocal laser scanning microscope with a 60x/1.27
Plan Apo IR Water immersion objective (SR Plan Apo IR AC, Nikon)
using a galvano scanner. A wavelength of 637 nm (LU-N4 Laser Unit)
was used for excitation of DiD. Fluorescence signals were detected with
a Multi-Alkali PMT (A1-DUG-2 GaAsP Multi Detector Unit). A stack of
19.5 μm above the glass surface with a step size of 0.5 μm at Nyquist
resolution was recorded and a maximum intensity projection was cre-
ated for visualization. All imaging was performed at RT.
2.5.6. Pharmacological studies in HFD-induced obese/diabetic mice
Male C57BL/6J mice (8 weeks old) were randomly housed (five
mice per cage). After an acclimation period (2 weeks) with a normal
chow diet (AIN93Mi, Research Diets, USA), the mice were fed a HFD for
10 weeks. The cages were randomly divided into 5 groups (10 mice per
group) before the experiments. The mice underwent an overnight fast
prior to oral gavage with free drug solution (EXE) (dose: 500 μg/kg),
non-PEGylated or PEGylated drug-loaded nanosystems (EXE RM LNC or
EXE RM LNC PEG) (dose: 500 μg/kg), or the empty PEGylated nano-
system (RM LNC PEG) (dose: equivalent nanocapsule concentrations to
the other groups). The control HFD group was orally administered an
equivalent volume of sterile water. An oral glucose tolerance test
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(OGTT) was performed 1 h after oral administration of the above-
mentioned formulations as previously described [11]. Briefly, glucose
was orally administered (2 g/kg), and then blood glucose determined
with a glucose meter (Accu Check, Roche, Switzerland), measuring the
blood from the tip of the tail vein 30 min prior to glucose load
(−30 min) and 0, 15, 30, 90 and 120 min after glucose administration.
The plasma insulin and total GLP-1 levels were also tested in plasma
from blood samples collected from the tail vein at −30 min and 15 min
using ELISA kits (Mercodia, Uppsala, Sweden and Meso Scale Delivery,
USA, respectively). The insulin resistance index was calculated by
multiplying the AUC of both blood glucose and insulin during OGTT. At
the end of the OGTT test, the mice were anesthetized with isoflurane
(Forene, Abbott, England), and blood samples were collected from the
portal vein. Active GLP-1 levels were tested by ELISA (Meso Scale De-
livery, Gaithersburg, USA).
2.5.7. Pharmacokinetics study in obese/diabetic mice
Male C57BL/6J mice (8 weeks old) were housed for 2 weeks of
acclimation and randomly divided into two groups (10 mice per time
point). Next, the mice underwent a HFD feeding for 10 weeks, as de-
scribed in the previous section. All mice were fasted overnight with free
access to sterile MilliQ water before oral gavage. Exenatide in solution
and EXE RM LNC PEG were orally administered at a dose of 500 μg/kg.
At predetermined time points (0, 0.5, 1, 1.5, 2, 4, 6 and 8 h), blood
samples were collected from the tip of the tail vein, centrifuged (1500 g,
10 min at 4 °C) and subjected to plasma extraction followed by storage
at −80 °C until further analysis. Exenatide plasma concentrations were
determined using ELISA kits (EK-070-94, Phoenix Europe GmbH,
Karlsruhe, Germany).
2.5.8. Long-term treatment in obese/diabetic mice with different oral
administration frequencies
Male C57BL/6J mice (8 weeks old) were randomly divided into
seven groups (10 mice per group) and housed at five per cage with free
access to sterile food (AIN93Mi; Research Diet) (control diet) and sterile
water. After 2 weeks of acclimation, the mice underwent 10 weeks of
HFD or a normal control diet. After this period, the mice were treated
with our formulations for an additional month, continuing with the
HFD feeding (14 weeks of HFD in total). During this month, the mice
were orally administered daily (D) or once every two days (T) at 4 pm
(i) empty or drug-loaded PEGylated formulations (500 μg/kg dose) with
daily treatment at the equivalent nanocapsule concentrations (RM LNC
PEG-D or EXE RM LNC PEG-D), and (ii) non-PEGylated, PEGylated
drug-loaded formulations (500 μg/kg dose) or empty PEGylated fo-
mulation with treatment every other day at the equivalent nanocapsule
concentrations (EXE RM LNC-T, EXE RM LNC PEG-T, or RM LNC PEG-
T). The control groups (healthy and HFD) were orally administered an
equivalent volume of sterile Milli-Q water daily. During this 4-week
treatment period, the body weight of the mice was recorded daily, and
glycemia was monitored once per week. Mice were fasted once per
week for 6 h prior to the glucose test.
2.6. Statistical analysis
The GraphPad Prism 8 program (CA, USA) was used for the data
analyses. The Grubbs test for outlier detection in each group was per-
formed prior to all analyses. Before preforming the analysis, when there
was a significant difference in the variance among groups, log-trans-
formation was used to normalize the values. Statistical analyses were
conducted using a two-way or one-way ANOVA followed by Tukey's
Fig. 1. Targeting strategies towards increased L cell stimulation to achieve increased endogenous GLP-1 secretion. (A) Graphic description of the two steps used to
prepare L cell-targeted nanocarriers. Step one: provision of the nanosystem with stealth properties (PEGylation) aimed at (i) increasing the mucopenetration, (ii) thus
further enhancing GLP-1 secretion by increasing the number of nanocarriers able to gain access to L cells and ultimately (iii) prolonging the blood circulation of the
nanosystems upon intestinal absorption. Step two: grafting of propionate on the surface of the nanosystems to improve L cell active targeting and to strengthen the
GLP-1 secretory effect. (B) Schematic representation of exenatide-loaded RM LNC PEG and RM LNC PEG-PRO. (C) Physicochemical characterization of empty, DiD-
labeled or exenatide-loaded RM LNC after including the different surface modifications (mean ± SEM; n = 9). For the schematic representation of EXE RM LNC
please refer to Ref. [11].
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post hoc test for studies containing more than two groups, and the t-test
or Mann-Whitney test for two groups. The nonparametric test was
conducted when there was a significant difference in variance between
groups even after normalization. Statistical significance was considered
at p < 0.05. All data are expressed as the mean ± standard error of
mean (SEM).
3. Results
3.1. Preparation and characterization of PEGylated nanoparticles with
propionate as a targeting moiety
We first encapsulated exenatide (a GLP-1 analog) into lipid nano-
capsules (LNC) following a previously described procedure to obtain
200-nm-particle-size nanocarriers [11]. This nanoparticle size was se-
lected based on our previous studies demonstrating the effect of lipid
nanocapsules with this nanoparticle size on GLP-1 secretion [11,22]. To
develop L cell-targeted lipid-based nanocapsules, we selected DSPE-
PEG2000 as a PEGylation linker to provide the nanocapsules with an
enhanced capacity for mucus diffusion (Fig. 1A–B) [24]. The post-in-
sertion method was selected to ensure the PEG chains were localized
only on the surface rather than retained within the particle core. We
used both DSPE-PEG2000-CH3 and DSPE-PEG2000-CH2-CH2-COOH, the
latter to provide specific targeting to L cell GPCRs present on their
surface. The physicochemical properties of empty lipid nanocapsules
were assessed before (RM LNC) and after the post-insertion of both
DSPE-PEG2000-CH3 and DSPE-PEG2000-CH2-CH2-COOH (RM LNC PEG
and RM LNC PEG-PRO, respectively) (Fig. 1C). Blank LNC presented an
~200-nm particle size and a narrow size distribution (PDI = 0.18).
These data are in accordance with our previous results [11]. After in-
cubation of LNC with biofunctional polymers, we observed an increase
in size of ~18 nm and ~27 nm for RM LNC PEG and RM LNC PEG-PRO,
respectively. The zeta potential values decreased significantly from
−0.94 mV (RM LNC) to −9.93 mV (RM LNC PEG). The surface charge
of RM LNC PEG-PRO decreased even more, reaching −18.20 mV in the
presence of the fatty acid. We obtained a similar particle size and zeta
potential after labeling the nanocarriers with DiD when compared to
the respective empty nanocapsules (Fig. 1C). Additionally, there was
also no significant influence on the size and surface charge of the na-
nocapsules when encapsulating exenatide within PEGylated nano-
capsules (EXE RM LNC PEG) (Fig. 1C).
To quantify the targeting capacity of propionate, we used empty
PEGylated polymeric PLGA nanoparticles (PLGA NPs) with or without
propionate (PLGA-PEG NPs and PLGA-PEG-PRO NPs, respectively)
(Supplementary Fig. S1A). We selected these polymeric nanocarriers for
this purpose because they do not trigger GLP-1 secretion by L cells
when non-targeted [25]. We prepared PLGA-PEG NPs and PLGA-PEG-
PRO NPs presenting a particle size of ~220 nm with a narrow size
distribution (PDI = 0.1) (Fig. S1B) to compare targeted polymeric
nanoparticles with targeted lipid nanocapsules. The zeta potential of
PLGA-PEG-PRO NPs decreased from −11.30 mV (PLGA-PEG NPs) to
−23.50 mV after the grafting of propionate (Supplementary Fig. S1B).
3.2. (Targeted) PEGylated NPs induce GLP-1 secretion both in vitro and in
vivo
We first investigated the ability of unloaded, PEGylated and pro-
pionate-grafted RM LNC to induce GLP-1 stimulation in vitro in GLUTag
cells (murine L cells). We used a nanoparticle concentration ranging
from 0.5 mg/mL to 2 mg/mL, after observing no evidence of cyto-
toxicity at concentrations below 4 mg/mL (Supplementary Fig. S2). As
shown in Fig. 2A, all lipid-based formulations significantly increase
endogenous GLP-1 secretion in vitro in L cells regardless of the nano-
particle concentration (**p < 0.05). However, stimulation of GLP-1
secretion did not differ significantly among the tested groups, regard-
less of the incorporation of DSPE-PEG2000 or DSPE-PEG2000-propionate
on the surface of the nanocapsules. Thus, these strategies were not able
to strengthen the nanocarrier's physiological ability to trigger GLP-1
stimulation in vitro. This observation of PEGylation indirectly leading to
increased nanoparticle cell uptake has been reported previously [26].
To further confirm the capacity of the grafted ligand (propionate) to
stimulate L cells, we also examined the L cell stimulation exerted by
targeted and non-targeted PEGylated PLGA NPs. Plain PLGA NPs were
found to be inert with respect to L cell stimulation [25]. Hence, if in-
creased GLP-1 secretion was to be observed using propionate-grafted
PLGA NPs, this effect could be attributed to the ligand. PEGylated PLGA
NPs failed to induce GLP-1 secretion compared with the control group
for all nanoparticle concentrations tested (p > 0.05) (Fig. 2B). The
results were comparable to those observed for plain PLGA NPs [25].
Moreover, PLGA-PEG NPs grafted with propionate also did not induce
GLP-1 secretion in GLUTag cells in vitro (p > 0.05), further demon-
strating that the introduction of propionate as a ligand on the surface of
nanoparticles was not sufficient to activate the corresponding GPCRs on
the surface of L cells, thus inducing GLP-1 secretion. For comparison,
we also tested the GLP-1 secretion induced on murine L cells by tar-
geting PEGylated PLGA NPs with capric acid (medium/long-chain fatty
acid that binds to GPR84 (PLGA-PEG-CAP NPs)). This ligand also failed
to trigger GLP-1 stimulation in murine L cells in vitro (Supplementary
Fig. S3).
Despite the discouraging results for increased GLP-1 secretion by
PEGylated lipid nanocapsules in vitro, and no effect of PLGA NPs, we
tested whether these nanocarriers could further strengthen and/or in-
duce GLP-1 stimulation in vivo in normoglycemic mice. When orally
administered to normoglycemic mice, both PEGylated lipid nano-
capsules (RM LNC PEG and RM LNC PEG-PRO, respectively) and non-
PEGylated lipid nanocapsules (RM LNC) significantly increased GLP-1
levels 60 min post-administration (*p < 0.05) (Fig. 2C). Notably, RM
LNC PEG increased GLP-1 levels up to ~ 8-fold at 60 min, whereas RM
LNC PEG-PRO had the same effect as the original unmodified RM LNC,
increasing GLP-1 secretion up to ~ 4-fold compared with the untreated
control group. Furthermore, only RM LNC PEG prolonged this effect at
180 min (*p < 0.05) when compared to the control group. Although
PEGylated NPs did not exert a significant effect in vitro when compared
to non-PEGylated NPs (Fig. 2A), PEGylation could significantly improve
and prolong the ability of the nanocarriers to induce GLP-1 secretion in
vivo. However, further grafting of propionate on PEGylated RM LNC not
only could not activate the GPCRs on the surface of L cells to trigger
more GLP-1 secretion but also failed to achieve the same effect as PE-
Gylated RM LNC. Moreover, when orally administering PEGylated
polymeric PLGA NPs (with or without propionate), both PLGA NPs
failed to increase GLP-1 secretion in normoglycemic mice (values too
low to be detectable, below 0.98 pg/mL), which further confirmed that
propionate decoration on the surface of the nanocarriers had no L cell-
targeting effect. However, it should be taken into account that the
concentration of propionate on the surface of the nanocarriers might be
too low to attain the effective concentration of propionate needed to
exert an effect on L cells (140 mmol/L in mice [27]). Thus, the dose of
propionate within the nanocapsules could be too low to induce the
desired effect.
3.3. Nanoparticle distribution in the small intestine and colon of obese/
diabetic mice
We tracked the distribution of the nanocapsules in different seg-
ments of the gut after oral gavage in vivo in 10-week HFD-fed mice. The
accumulation of DiD-labeled nanocapsules within the small intestine
and the colon upon oral administration to HFD mice is depicted in
Fig. 3. All the fluorescent particles (DiD RM LNC, DiD RM LNC PEG and
DiD RM LNC PEG-PRO) could be found in the duodenum, in which the
DiD RM LNC PEG group showed the strongest red fluorescence (DiD)
compared with the other groups. RM LNC PEG-PRO seemed to fail to
reach the surface of L cells and thus failed to reach the desired targeting
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goal when grafting fatty acids (propionate) on the surface of lipid na-
nocapsules.
To investigate a potential difference in mucus diffusion, we per-
formed single particle tracking. Therefore, particles were mixed with
small intestinal mucus, placed in a custom-made glass chamber and
visualized on a spinning disk microscope. However, it was not possible
to determine the particle diffusion in vitro in small intestinal mucus of
mice due to a strongly reduced amount of observed particles compared
with the particles in water (Supplementary Fig. S4A). With confocal
microscopy, large structures with increased fluorescence intensity
compared with mucus alone were observed (Supplementary Fig. S4B)
for all formulations, indicating aggregation and/or binding to mucus
constituents. Since the mobility of individual nanocapsules could not be
investigated, it was not possible to conclude if there were any differ-
ences in net mobility between the different formulations.
DiD-labeled RM LNC were observed mainly in the duodenum and
hardly in the jejunum 1 h post-administration. Interestingly, 1 h after
the treatment, only RM LNC PEG were able to pass through the in-
testinal epithelia in the jejunum, with a high level of red fluorescence
observed in the epithelial basal layer (arrows) compared with the other
groups. Additionally, only RM LNC PEG were able to pass through the
whole small intestine (duodenum, jejunum and ileum) and reach the
colon. These data could explain why PEGylated RM LNC considerably
increased whereas RM LNC PEG-PRO showed no improvement of GLP-1
secretion. Complementary images on nanoparticle distribution are
depicted in Supplementary Fig. S5.
3.4. Pharmacological and pharmacokinetics studies in obese/diabetic mice
As we observed no benefit of grafting propionate on the surface of
PEGylated lipid nanocapsules with regard to L cell stimulation, we
pursued pharmacological and pharmacokinetic studies with PEGylated
nanocapsules alone. Prior to the evaluation of the efficacy of the for-
mulation in vivo, we demonstrated the stability of the formulation in
vitro in simulated gastric and intestinal fluids, and we evaluated the
release profile of exenatide (Supplementary Fig. S6).
To determine the therapeutic efficacy of exenatide-loaded RM LNC
PEG (EXE RM LNC PEG) on controlling the post-prandial hyperglycemia
in type 2 diabetic mice, the pharmacodynamics profile was performed
in 10 weeks HFD-fed mice. We administered a single dose of the na-
nocapsules prior to an oral glucose tolerance test (OGTT). The exena-
tide dose of 500 μg/kg for the free drug solution and drug-loaded for-
mulations (including EXE in solution, EXE RM LNC and EXE RM LNC
PEG, respectively), empty RM LNC PEG (equal volume as per drug-
loaded nanocapsules), or an equivalent water volume was orally ad-
ministered 60 min before an oral glucose challenge (glucose con-
centration: 2 g/kg). The time point of glucose administration corre-
sponded to 0 h (Fig. 4A). The plasma glucose profile of drug solution-
treated mice showed a similar trend as the HFD-fed mice that received
water. Conversely, all the nanocapsule-treated groups, including EXE
Fig. 2. Effect of PEGylated NPs (with or without propionate grafted as a ligand) on GLP-1 stimulation in GLUTag cells (murine L cells) and in normoglycemic mice.
(A) Effect of PEGylated RM LNC (with or without propionate grafted as a ligand) on GLP-1 stimulation in murine GLUTag cells after 2 h of co-incubation with
increasing nanocapsule concentrations from 0.5 to 2 mg/mL (mean ± SEM; n = 4; N = 3). (B) Effect of polymeric PLGA-PEG NPs (with or without propionate
grafted as a ligand) on GLP-1 secretion from GLUTag cells after 2 h of co-incubation with an increasing nanoparticle concentration from 0.1 to 3 mg/mL
(mean ± SEM; n = 4; N = 3). (C) Total GLP-1 levels in healthy control mice 60 and 180 min post-oral gavage with RM LNC, RM LNC PEG and RM LNC PEG-PRO
using the same nanocapsule dose (1.62 mg/g) (mean ± SEM; n = 8). Different superscript letters represent significant differences between the groups (*p < 0.05)
based on two-way analysis of variance followed by Tukey's post hoc test (A), the Mann-Whitney test (B) or one-way ANOVA followed by Tukey's post hoc test (C).
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RM LNC, EXE RM LNC PEG and empty RM LNC PEG, could markedly
lower blood glucose levels and the glucose area under the curve (AUC)
(Fig. 4A). It is remarkable that empty RM LNC PEG had a similar effi-
cacy for reducing plasma glucose levels and a similar AUC compared
with exenatide-loaded RM LNC, indicating that the hypoglycemic effect
achieved by the nanocarrier alone after PEGylation was comparable to
non-PEGylated nanocarriers encapsulating the drug. Hence, the GLP-1
levels secreted by PEGylated nanocapsules (Fig. 2C) were found to be
therapeutically relevant regarding a glucose lowering effect. It is worth
noting that, among all the tested formulations, only EXE RM LNC PEG
orally treated mice showed significantly decreased plasma glucose le-
vels throughout the overall OGTT test compared with untreated HFD
mice.
Additionally, the total GLP-1 levels (Fig. 4B) were also significantly
improved in all nanocapsule-treated groups compared with the control
groups (*p < 0.05). Although the increase in total GLP-1 levels in the
EXE RM LNC group did not reach significant differences compared with
the HFD group analyzed by the Kruskal-Wallis and Dunn's post hoc
tests, significant differences were observed when the Mann-Whitney
test was applied (p = 0.008) (Fig. 4B). The active GLP-1 concentration
measured in the portal vein (3 h post-administration of the formulation)
compared with the untreated HFD mice was also significantly increased
in EXE RM LNC PEG-treated mice after the OGTT test (*p < 0.05)
(Fig. 4C). Although there were no significant differences between the
RM LNC PEG and HFD when analyzing the data by one-way ANOVA,
we encountered significant differences between these groups by the
Student's t-test (p = 0.028). These data would confirm that PEGylation
was able to improve the ability of the nanosystems to stimulate GLP-1
release and prolong this effect under pathological conditions. We en-
countered no differences among groups regarding insulin levels
(Fig. 4D). However, EXE RM LNC PEG could dramatically reduce the
insulin resistance index compared with the untreated diabetic mice
(Fig. 4E). We encountered significant differences between these groups
by the Student's t-test (p = 0.035 and p = 0.023, respectively), despite
no significant differences between EXE RM LNC and RM LNC PEG by
one-way ANOVA. Strikingly, we obtained a comparable result with
unloaded PEGylated RM LNC when compared to EXE-loaded nano-
capsules, further confirming the therapeutic relevance of the increased
GLP-1 levels obtained through PEGylation.
Of note, it is our understanding that the most suitable statistical test
regarding the size of our study (groups and number of animals per
group) is ANOVA (parametric) or Kruskal-Wallis analysis (non-para-
metric). However, increasing the number of groups also increases the
variability. We wanted to underscore that the large number of groups
and the variability of the study could have hindered the identification
of more significant differences among the groups. We used the
Fig. 3. In vivo distribution within the small intestine and the colon of mice. Representative images of the fluorescent nanocapsule (red) distribution in the duodenum,
jejunum, ileum and colon in 10-week HFD obese/diabetic mice 1 h after the oral gavage of MilliQ water, DiD RM LNC, DiD RM LNC PEG and DiD RM LNC PEG-PRO
(1.62 mg/g nanoparticle dose) (n = 4). The images show merged fluorescent nanocapsules (red)/DAPI (blue) staining of the cell nucleus. White arrows point to lipid-
based nanocapsules. Scale bar = 50 μm. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
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appropriate statistical test in the figure, but we wanted to highlight the
differences encountered among groups, pointing to a strong physiolo-
gical effect, as shown by the differences encountered when conducting
the Student's t-test or Mann-Whitney test (parametric and non-para-
metric tests comparing two groups only).
To investigate the oral delivery of exenatide via PEGylated RM LNC,
a pharmacokinetic study was performed to evaluate the oral absorption
of exenatide in chronic diabetic mice (10 weeks of HFD; n = 10 per
point) after oral administration of a single dose of 500 μg/kg exenatide
via drug solution or within RM LNC PEG (EXE RM LNC PEG) (Fig. 4F).
A different pattern of exenatide absorption was observed in obese/
diabetic mice after oral gavage of drug solution alone or EXE RM LNC
PEG. When orally administered as a solution, the plasma concentration
of exenatide remained unchanged throughout the testing period. In
comparison, EXE RM LNC PEG elicited greater systemic absorption of
the peptide after oral administration for 8 h, with a Tmax and Cmax of 1 h
and 27.91 ± 1.22 ng/mL, respectively. Supplementary Table S1
summarizes the calculated parameters obtained in this pharmacokinetic
study. One should note that a different exenatide pharmacokinetic
profile (e.g., different Cmax, AUC, Tmax) was observed after oral ad-
ministration of EXE RM LNC PEG versus EXE RM LNC [11], indicating
that PEGylation extended the circulation time of the formulation (t1/2
of the drug-loaded formulation prolonged from 1.68 ± 0.35 to
5.69 ± 1.02 h) and then increased the systemic absorption of the
encapsulated peptide (AUC increased from 11.79 ± 2.73 to
27.91 ± 1.22 ng mL−1·min−1).
3.5. Long-term treatment with PEGylated lipid nanocapsules in obese/
diabetic mice
To investigate the impact of the increased GLP-1 secretion observed
after PEGylation on glucose metabolism, we performed a long-term
treatment (one month) in diabetic mice (10 weeks HFD), administering
exenatide-loaded or unloaded RM LNC PEG (500 μg/kg) with different
administration frequencies (daily or once every other day) (14 weeks of
HFD in total, administrations for 4 weeks from week 10). The mice
treated less frequently by oral administration (once every other day)
(EXE RM LNC PEG; 500 μg/kg), or with identical amounts of unloaded
PEGylated nanocapsules (RM LNC PEG), were also compared with those
that received non-PEGylated EXE-loaded nanocapsules (EXE RM LNC;
500 μg/kg) following the administration regimen.
The plasma glucose levels were monitored weekly during the 4
weeks of treatment and are depicted in Supplementary Fig. S7. The
plasma glucose and insulin levels and the calculated HOMA-IR after a 4
Fig. 4. Pharmacological and pharmacokinetics studies in obese/diabetic mice after a single orally administered dose. (A) Blood glucose values (mg·dL−1) and mean
AUC (mg·dL·min−1) were tested 30 min before and 120 min after glucose administration (n = 7–8). (B) Plasma total GLP-1 concentrations were measured 30 min
before and 15 min after glucose administration (n = 6–8). (C) Active GLP-1 levels measured in the portal vein of obese/diabetic mouse after OGTT (3 h post-
administration of the formulation) (n = 6–8). (D) Insulin concentrations were measured in plasma collected from blood from the tail vein 30 min before and 15 min
after oral glucose administration (n = 6–8). (E) Insulin resistance index (n = 7–8). (F) Plasma exenatide concentration-time profile and exenatide AUC in diabetic
mice (10 weeks of HFD feeding) after oral administration of the drug solution or drug-loaded PEGylated nanocapsules (EXE and EXE RM LNC PEG, respectively)
(dose: 500 μg/kg) (n = 9–10). Data are shown as the mean ± SEM. Different superscript letters indicate a significant difference among the groups (*p < 0.05) by
two-way analysis of variance (ANOVA) and Tukey's post hoc test (A, F), the Kruskal-Wallis followed by Dunn's post hoc test (B) or one-way ANOVA followed by
Tukey's post hoc test (C–E).
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weeks of treatment are depicted in Fig. 5. The PEGylated groups
(loaded or unloaded) administered on a daily basis and the EXE-loaded
PEGylated group administered every other day exhibited comparable
glucose plasma levels. These levels were in turn comparable to the non-
obese/diabetic untreated control mice (p > 0.05, Fig. 5A). It is note-
worthy that only when PEGylated nanocapsules were encapsulating
EXE were effective for lowering glucose plasma levels following a long-
term treatment. More importantly, they were efficient even with less
frequent administration, which was the main goal of the present study
(Fig. 5A). Additionally, these groups exhibited equivalent insulin re-
sistance, as analyzed by homeostatic model assessment of insulin re-
sistance (HOMA-IR), which were comparable to the control values ob-
tained for the healthy control group (p > 0.05) (Fig. 5C). Compared
with the HFD group, the reduction among these groups was not sta-
tistically significant using the Kruskal-Wallis followed by Dunn's post
hoc test (Fig. 5C). However, significant differences were observed when
the Mann-Whitney test was used (p = 0.0012 for EXE RM LNC PEG-D
versus HFD, p = 0.0003 for RM LNC PEG-D treatment versus HFD, and
p = 0.05 for EXE RM LNC PEG-T treatment versus HFD, respectively).
4. Discussion
The aim of the present study was to increase the L cell stimulation
exerted by our nanocarriers, thus increasing the induced secreted GLP-1
levels. This would allow us to prolong the in vivo antidiabetic effect
exerted by our nanosystem towards less frequent peptide administra-
tions. To achieve this goal, the aim of this study was to develop tar-
geted-nanosystems towards increased L cell stimulation. Based on the
literature [29], we chose propionate as the fatty acid for grafting on the
surface of our lipid-based nanocapsules, as it is known to be a potent
highly effective ligand for GPCRs located on the surface of L cells.
We first evaluated the ability of propionate-targeted lipid-based
formulations to stimulate GLP-1 secretion by L cells in vitro in murine
GLUTag cells. All tested lipid-based nanocarriers effectively increased
the secretion of GLP-1 by L cells, regardless of being grafted with
propionate (Fig. 2A). Indeed, grafting the surface of lipid nanocapsules
with propionate did not provide any additional advantage compared
with plain nanocapsules. However, as we pointed out, the propionate
dose administered within the nanocapsules might be insufficient to
induce an effect. The same results were observed when PLGA-based
nanoparticles were grafted with both propionic and capric acid
(Fig. 2B). As PLGA nanoparticles failed to increase GLP-1 in vitro, we
tested the effect of lipid-based nanocapsules (propionate-targeted or
not) in vivo in normoglycemic mice. Surprisingly, we found out that RM
LNC with PEG alone (the linker used to graft propionate on the surface
of LNC) (RM LNC PEG) significantly increased secreted GLP-1 levels
from ~ 4-fold to ~ 8-fold at 60 min, prolonging the effect observed for
RM LNC and increasing the effect at least up to 180 min (Fig. 2C).
Propionate-grafted nanocapsules (RM LNC PEG-PRO) significantly in-
creased GLP-1 secretion compared with the control untreated group at
60 min. However, the effect was significantly lower than the effect
exerted by PEGylated lipid nanocapsules alone and was not prolonged
(p > 0.05 at 180 min) (Fig. 2C). We further investigated the locali-
zation of nanocapsules (fluorescence) in 10-week HFD-treated obese/
diabetic mice 1 h after oral gavage of the formulation (Fig. 3). We chose
to evaluate the effect directly in a diabetic model and not in normo-
glycemic mice because the number of L cells is known to be increased in
the pathological context [30]. After 1 h of treatment, DiD-RM LNC PEG
showed the strongest red fluorescence (DiD) in the intestinal lumen,
and they were able to pass through the whole small intestine (duo-
denum, jejunum and ileum) to finally reach the colon. It should be
noted that the colon harbors the highest amount of enteroendocrine L
cells in the entire gut [31].
The ultimate goal of our study was to prolong the in vivo anti-
diabetic effect exerted by our nanosystem towards less frequent peptide
administrations. For this purpose, once confirmed propionate-targeted
nanoparticles were not exerting the desired effect, we pursued studies
with PEGylated lipid nanocapsules. We evaluated the ability of
PEGylated nanocapsules and their non-PEGylated counterparts, EXE-
loaded or unloaded, to improve glycemia in vivo in obese/diabetic mice
(10 weeks of HFD feeding) following acute or chronic treatment. For
the acute treatment with a single dose, all tested nanoparticles,
PEGylated or not, were able to normalize blood glucose levels, sig-
nificantly increasing GLP-1 secretion. However, only PEGylated nano-
particles were able to significantly increase active GLP-1 secretion, and
the secreted circulating GLP-1 levels were higher than those observed
for the non-PEGylated nanoparticles. We observed a different exenatide
pharmacokinetic profile for EXE RM LNC PEG compared with our
previous studies with EXE RM LNC [9]. The PEGylation extended the
circulation time of the formulation (t1/2 of the drug-loaded formulation
prolonged from 1.7 ± 0.4 to 5.7 ± 1.0 h) and then increased the
systemic absorption of the encapsulated peptide (AUC increased from
Fig. 5. Effect of PEGylated and non-PEGylated EXE-loaded lipid nanocapsules with different oral administration frequencies on the suppression of hyperglycemia and
hyperinsulinemia in HFD diet-induced diabetic mice via long-term therapy. (A) Plasma glucose values (mg⋅dL−1) after 4 weeks of administration (HFD feeding for 14
weeks in total) (mean ± SEM; n = 7–10). (B) Insulin concentrations were tested in the plasma from blood retrieved from the tail vein (mean ± SEM; n = 6–9). (C)
HOMA-IR was calculated using the equation [fasting glucose in mg/dL × fasting insulin in ng/mL]/405 as previously defined [28] (mean ± SEM; n = 8–9).
Different superscript letters show statistically significant differences among the groups (*p < 0.05) based on two-way analysis of variance followed by Tukey's post
hoc test (A), or the Kruskal-Wallis followed by Dunn's post hoc test (B, C).
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11.8 ± 2.7 to 27.9 ± 1.2 ng mL−1·min-1).
To further demonstrate that the PEGylated nanosystem could effi-
ciently prolong the in vivo antidiabetic effect and help minimize the
administration frequency, we performed a chronic/long-term therapy
consisting of a 4 weeks of treatment with a protocol including two
different administration regimens: once daily (D) or once every other
day (T). After a 4-week treatment, EXE RM LNC PEG-T (administered
once every other day), RM LNC PEG-D and EXE RM LNC PEG-D (ad-
ministered daily) mice showed normalized plasma glucose levels
(Fig. 5A), which significantly reduced insulin resistance (measured by
HOMA-IR, Fig. 5C). We were thus able to obtain comparable results
among PEGylated nanocapsules, reaching basal glucose levels even
with less frequent administration when encapsulating EXE. Interest-
ingly, when administered once daily, the unloaded PEGylated nano-
capsules were also able to reach basal glucose levels and significantly
reduce insulin resistance, confirming that the increase in GLP-1 secre-
tion (~8-fold) was a sufficient stimulus for lowering glucose levels.
Moreover, this effect was prolonged over time, allowing us to reduce
the administration frequency.
5. Conclusion
In conclusion, we reached our goal of increasing GLP-1 secretion
and prolonging the antidiabetic effect of our formulation via
PEGylation. Although many questions remain (e.g. the exact me-
chanism of action, potential toxicity to the gastrointestinal tract fol-
lowing frequent administrations, anti-PEG antibodies in the clinic), we
have demonstrated our proof-of-concept that we can decorate the sur-
face of our nanocapsules to modulate their effect on GLP-1 secretion.
This finding brings hope for the treatment not only of T2DM but also
other gastrointestinal diseases that require the secretion of other gas-
trointestinal peptides (e.g., inflammatory bowel diseases), as well as the
use of nanomedicine for oral peptide delivery. All these developments
will help foster the translation of this approach to the clinics.
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